Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Legend Biotech (NASDAQ: LEGN) has announced an upcoming investor event during the 2025 ASCO Annual Meeting in Chicago.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Legend Biotech (NASDAQ: LEGN) has announced an upcoming investor event during the 2025 ASCO Annual Meeting in Chicago. The company will host a live webcast on June 1, 2025, at 6:00 p.m. CT, featuring CEO Ying Huang and CMO Mythili Koneru, who will be joined by expert clinicians to discuss updates from the CARTITUDE development program. Investors can access the webcast through a provided weblink or the company's website under Events and Presentations.
Details
News Market Reaction – LEGN
The recorded move for LEGN in the trading session of this news was +4.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 p.m. CT (7:00 p.m. ET) during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinicians as they review the latest updates from the CARTITUDE development program.
Investors and other interested parties may join the live webcast through this weblink or visit Legend Biotech’s website under Events and Presentations.
About Legend Biotech
With over 2,600 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.